Metraipolis › archive › dc_7e49b13f79df

Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system — Europe PMC PMID:41473061

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41473061
DOI
10.1016/j.xjon.2025.10.003
License (as archived)
solo-consultazione
Archived
2026-11-09T07:09:38.313Z
SHA-256 of the archived text
6be98a8d1556f7e51a297e40241a8f1cf2b1e5b0814fdedeb60aebbd4dc7ade8
Stable URL of this page
https://metraipolis.com/documento/dc_7e49b13f79df

How to cite

Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system — Europe PMC PMID:41473061 — Europe PMC (en), https://europepmc.org/article/MED/41473061 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7e49b13f79df (Metraipolis archive dc_7e49b13f79df, sha256 6be98a8d1556f7e51a297e40241a8f1cf2b1e5b0814fdedeb60aebbd4dc7ade8)
BibTeX
@misc{dc7e49b13f79df,
  title = {Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system — Europe PMC PMID:41473061},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41473061},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7e49b13f79df; sha256 6be98a8d1556f7e51a297e40241a8f1cf2b1e5b0814fdedeb60aebbd4dc7ade8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41473061. Agents can read the archived copy with the MCP tool read_document.